#USA #Menlo Park #BillionToOne #Dr. Haywood Brown #prenatal care

BillionToOne Strengthens Leadership with New CMO

BillionToOne, an innovative molecular diagnostics firm known for its commitment to making advanced testing accessible, recently announced a significant addition to its executive leadership team. Dr. Haywood L. Brown has been appointed as the Chief Medical Officer for Prenatal Services as the company celebrates a landmark achievement of one million UNITY tests performed.

Dr. Brown brings an impressive portfolio of experience to his new role, having dedicated over thirty years to improving maternal and fetal health. He has served various prestigious organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal Fetal Medicine (SMFM), and has held academic and clinical leadership roles that emphasize health equity within women's health.

Dr. Haywood Brown is not only recognized for his clinical acumen but also as an advocate for addressing healthcare disparities. His past tenure as ACOG’s 68th President highlighted his commitment to enhancing women's health equity, advocating for maternal mortality prevention, and pushing for healthcare reforms that benefit women nationwide. His insights are expected to propel BillionToOne's prenatal strategy, leveraging his extensive background in guiding educational initiatives for healthcare providers.

As the field of prenatal diagnostics evolves, BillionToOne is positioning itself at the forefront with its unique technology known as Quantitative Counting Templates (QCT™). This proprietary platform allows for the accurate counting of DNA molecules at a single-base-pair level. Dr. Brown envisions a future where comprehensive molecular diagnostics can profoundly impact prenatal assessments and outcomes.

BillionToOne’s flagship offering, the UNITY Fetal Risk™ Screen, stands alone in its capability to analyze fetal cell-free DNA. This innovative test provides valuable insights into potential fetal risks for chromosomal abnormalities without the need for invasive procedures or samples from male partners. It is particularly advantageous in areas lacking access to specialized maternal-fetal care, known as maternity care deserts.

Dr. Oguzhan Atay, co-founder and CEO of BillionToOne, expressed enthusiasm over Dr. Brown’s appointment: "We are honored to welcome Dr. Haywood Brown to BillionToOne. His experience and influence in the prenatal ecosystem align with our mission to enhance provider education and address the critical healthcare disparities we currently face."

In his own words, Dr. Brown remarked on the opportunity to utilize BillionToOne’s technology: "The precision and comprehensiveness of our molecular diagnostic platform marks a pivotal moment in prenatal screening. After decades in maternal-fetal medicine, I can truly appreciate the transformative potential of technologies that grant us detailed genetic insights non-invasively."

In addition to its prenatal services, BillionToOne also offers oncology solutions through its Northstar Select® and Northstar Response® products. The company’s commitment to delivering high-quality, actionable diagnostics has solidified its reputation in both prenatal and oncology markets, and it continues to pave the way for future advancements in molecular diagnostics.

As Dr. Brown steps into his new role, it is clear that his leadership will play a vital part in further sculpting the future of prenatal diagnostics at BillionToOne, ensuring that powerful and accurate testing becomes accessible to all, regardless of geographical or socio-economic barriers.

To discover more about BillionToOne and its pioneering work in molecular diagnostics, visit www.billiontoone.com.